What is Bio-options?
Bio-options operates as a specialized provider of high-quality human tissues and biological materials, serving as a vital link in the supply chain for molecular and genomic research. By maintaining a comprehensive biorepository that includes frozen and FFPE tissues, as well as blood samples, the company addresses the rigorous demands of modern biomedical investigation. Their unique physician-owned structure allows for a consultative, expert-led approach to sample procurement, ensuring that research institutions receive precisely characterized biospecimens. This operational excellence has positioned Bio-options as a reliable partner for scientists navigating the complexities of translational medicine and drug development.
How much funding has Bio-options raised?
Bio-options has raised a total of $102K across 1 funding round:
Debt
$102K
Debt (2021): $102K with participation from PPP
Key Investors in Bio-options
PPP
Public-Private Partnership
What's next for Bio-options?
With this late-stage financing, Bio-options is well-positioned to scale its biorepository operations and expand its network of community-based hospital partnerships. The strategic deployment of this capital will likely focus on enhancing sample processing capabilities and integrating advanced digital tracking systems to meet the increasing demand for high-fidelity biological data. As the company moves into this next phase of growth, it is expected to further refine its consultative service model, potentially exploring new therapeutic areas or expanding its footprint in the global research market. The focus remains on maintaining the integrity of its biological assets while accelerating the pace of discovery for its institutional clients.
See full Bio-options company page
